Jane Street
ADAP

Jane Street’s Adaptimmune Therapeutics ADAP Stock Holding History

Jane Street’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,805,345
Closed -$365K – 10975
2025
Q3 		$365K Buy
+2,805,345
New +$385K ﹤0.01% 8522
2025
Q1 		– Sell
-326,937
Closed -$176K – 9302
2024
Q4 		$176K Buy
326,937
+152,780
+88% +$111K ﹤0.01% 8493
2024
Q3 		$166K Buy
174,157
+98,581
+130% +$112K ﹤0.01% 8769
2024
Q2 		$73.7K Buy
+75,576
New +$82.9K ﹤0.01% 8834
2024
Q1 		– Sell
-97,580
Closed -$77.4K – 9103
2023
Q4 		$77.4K Buy
+97,580
New +$55K ﹤0.01% 8672
2022
Q3 		– Sell
-44,086
Closed -$75K – 9607
2022
Q2 		$75K Buy
+44,086
New +$75.7K ﹤0.01% 8782
2022
Q1 		– Sell
-20,249
Closed -$76K – 10184
2021
Q4 		$76K Sell
20,249
-21,681
-52% -$98.7K ﹤0.01% 9366
2021
Q3 		$216K Buy
41,930
+11,234
+37% +$50.4K ﹤0.01% 8733
2021
Q2 		$130K Buy
30,696
+12,381
+68% +$60.1K ﹤0.01% 9140
2021
Q1 		$97K Sell
18,315
-10,058
-35% -$57.6K ﹤0.01% 8657
2020
Q4 		$153K Buy
+28,373
New +$154K ﹤0.01% 7071
2018
Q2 		– Sell
-14,947
Closed -$168K – 4894
2018
Q1 		$168K Buy
+14,947
New +$131K ﹤0.01% 4507

Other funds holding ADAP

JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
EF
Empirical Finance Havertown, Pennsylvania $2.13B AUM 29.56% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Jane Street's ADAP Position: Q4 2025 in Review

Jane Street sold out of Adaptimmune Therapeutics (ADAP) in Q4 2025, closing a stake of 2,805,345 shares — an estimated $365K sold.

Jane Street first reported a position in ADAP in Q1 2018 and held it in 12 quarters. The position peaked at $365K in Q3 2025. 10 funds tracked by Wall St. Rank hold ADAP as of Q4 2025.

  • Jane Street reported no remaining Adaptimmune Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Jane Street sold 2,805,345 Adaptimmune Therapeutics shares in Q4 2025, an estimated $365K.
  • Jane Street first reported a position in Adaptimmune Therapeutics in Q1 2018 and held it in 12 quarters.
  • Jane Street's Adaptimmune Therapeutics position peaked at $365K in Q3 2025.
  • 10 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2025.

Based on Jane Street's 13F filing for Q4 2025, filed 12 Feb 2026.